HCV NS5B polymerase inhibitors.
In the past decade, intensive efforts have focused on the discovery of both nucleos(t)ide and non-nucleoside inhibitors of the HCV NS5B polymerase. These efforts have resulted in several promising agents advancing in clinical development. This review traces the history of optimization of the chemical series that have led to the development of clinical candidates, and summarizes recent developments in the field, with emphasis on clinical efficacy and impact for future combination studies.
Watkins
William J
WJ
Gilead Sciences Inc, Foster City, CA 94404, USA. Will.watkins@gilead.com
Ray
Adrian S
AS
Chong
Lee S
LS
D000818:Animals; D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D016174:Hepacivirus / Q000187:drug effects / Q000472:pathogenicity; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D019384:Nucleic Acid Synthesis Inhibitors; D017361:Viral Nonstructural Proteins / Q000378:metabolism*; D012324:RNA-Dependent RNA Polymerase
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D019384:Nucleic Acid Synthesis Inhibitors; D017361:Viral Nonstructural Proteins; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase